Big gains could be just a click of the buy button away.
News & Analysis: Aimmune Therapeutics
AIMT earnings call for the period ending September 30, 2019.
A survey of allergists suggests Palforzia's launch could be more successful than expected.
How vaping risks may impact cannabis companies and Aimmune Therapeutics' plan to change how doctors treat peanut allergies.
Here's what a benign briefing document means, and what it doesn't.
The company's peanut allergen desensitization therapy took an indirect step forward.
Investors better get ready for a busy week ahead.
In the high-risk world of biotech investing, there are no guarantees of success. Still, sometimes investors can find places where the odds look reasonable enough to consider buying shares.
AIMT earnings call for the period ending June 30, 2019.
The Institute for Clinical and Economic Review questions the short-term risks of the biotech's drug.